

FMHL/SEC/SE/BM/FEBRUARY'17

February 9, 2017

The General Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Scrip Code: 523696
Sub: Outcome of the Board Meeting

Dear Sir

This is to inform you that the Board of Directors of the Company at their meeting held today i.e. February 9, 2017, *inter-alia*, considered and approved the Un-audited Financial Results for the quarter and period ended on December 31, 2016.

Please find enclosed Un-audited Financial Results along with the Limited Review Report thereon along with a copy of the press release being issued in this regard.

The meeting concluded at 5:00 p.m.

This is for your information and records please.

Yours faithfully

For Fortis Malar Hospitals Limited


Sumit Goel
Company Secretary



**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM
FINANCIAL RESULTS**

TO THE BOARD OF DIRECTORS OF FORTIS MALAR HOSPITALS LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **FORTIS MALAR HOSPITALS LIMITED** ("the Company"), for the quarter and nine months ended December 31, 2016 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)





Sriraman Parthasarathy
Partner
(Membership No. 206834)

CHENNAI, February 9, 2017
PS/MS/2017

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2016

No.	Particulars	Standalone			Standalone			(Rs. in lakhs except EPS)
		Quarter ended		December 31, 2015 (Unaudited)	Nine Months ended		December 31, 2015 (Unaudited)	
		December 31, 2016 (Unaudited)	September 30, 2016 (Unaudited)		December 31, 2016 (Unaudited)	December 31, 2015 (Unaudited)		
1	Income from Operations	3,624.45	3,651.64	3,310.34	10,570.49	9,609.81		
	a) Other Operating Income	2.52	2.62	1.60	6.02	5.95		
	Net Income from Operations	3,626.97	3,654.26	3,311.94	10,576.51	9,615.77		
2	Expenses							
	a) Purchase of Medical Consumables and Drugs	760.50	850.81	775.82	2,334.63	2,332.56		
	b) Changes in Inventories of Medical Consumables and Drugs	54.74	(51.05)	(69.20)	(29.28)	(237.22)		
	c) Employees Benefit Expenses	515.21	482.72	415.80	1,469.36	1,270.02		
	d) Professional Charges to Doctors	1,098.89	1,051.74	895.37	3,167.74	2,565.75		
	e) Clinical Establishment Fees	307.61	507.36	488.12	1,499.97	1,411.38		
	f) Depreciation and Amortization Expenses	100.98	99.77	79.64	294.61	236.54		
	g) Other Expenses	633.89	741.89	657.03	2,003.89	1,733.53		
	Total Expenses	3,676.62	3,683.24	3,242.58	10,741.02	9,560.56		
3	(Less) Profit from Operations before Other Income & Finance Costs (1-2)	(49.65)	(28.98)	69.36	(164.51)	755.21		
4	Other Income	181.55	196.07	187.14	563.85	578.58		
5	Profit before Finance Costs and Exceptional Items (3+4)	131.88	167.09	256.50	399.38	833.79		
6	Finance Cost	11.46	10.29	10.26	30.37	29.40		
7	Profit from Ordinary Activities After Finance Cost but before Exceptional Items (5-6)	120.42	156.80	246.24	369.01	804.39		
8	Exceptional Items	-	-	(51.15)	-	(51.15)		
9	Profit from Ordinary Activities before Tax (7-8)	120.42	156.80	195.09	369.01	753.24		
10	Tax expense	34.76	54.00	67.21	120.52	262.36		
11	Net Profit from Ordinary Activities After Tax (9-10)	85.66	102.80	127.88	248.49	490.88		
12	Other Comprehensive Income	(6.55)	(14.23)	(1.01)	(20.78)	6.95		
13	Total Comprehensive Income for the period (11+12)	79.11	88.57	126.87	227.71	496.84		
14	Paid up Equity Share Capital (Face Value Rs.10 each)	1,867.95	1,867.95	1,861.70	1,867.95	1,861.70		
15	Earnings Per Share (EPS) (of Rs. 10 each not annualised)	0.42	0.47	0.68	1.22	2.67		
	- Basic	0.42	0.47	0.68	1.22	2.67		
	- Diluted							



(Handwritten signature)

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2016

Notes :

- The above standalone unaudited financial results have been reviewed by the Audit and Risk Management Committee, approved and taken on record by the Board of Directors in their meeting held on February 9, 2017. The above results have also been subjected to a limited review by the Statutory Auditors of the Company.
- The Company adopted Ind AS from April 1, 2016 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. The reconciliation between standalone financial results for the quarter and period ended December 31, 2015 as previously reported (referred to as Previous GAAP) and Ind AS are as under:

Particulars	(Rs. in lakhs)	
	Quarter Ended December 31, 2015	Period Ended December 31, 2015
Net Profit under Previous GAAP	126.99	497.62
Actuarial Loss/(Gain) on employee defined benefit plans recognised in Other Comprehensive Income	1.01	(6.96)
Strategic timing of Clinical Establishment Fees	(0.86)	(2.66)
Fair value adjustments to Financial Assets	0.74	1.88
Net Profit for the period under Ind AS	127.88	489.88
Other Comprehensive Income	(1.01)	6.96
Total Comprehensive Income under Ind AS	126.87	496.84

- The Company has identified business segment which is "Health Care Services" as its primary segment and geographic segment as its secondary segment. The amounts appearing in the results relate to this single primary segment. Also Refer Note 4 below.
- The Board of Directors of the Company at its meeting held on August 19, 2016 approved the proposal for the sale of its hospital business by way of a slump sale to Fortis Healthcare Limited (FHL) pursuant to a composite scheme of Arrangement and Amalgamation between the Company, FHL and SRL Limited (SRL). Pursuant to the said composite scheme, the diagnostic business of FHL (including its investments held in SRL) shall get demerged into the Company in lieu of equity shares to be issued by the Company to the shareholders of FHL. The demerger shall be followed by SRL being merged with the Company as an integral part of the same composite scheme and shares of the Company to be issued to the eligible shareholders of SRL. The approval date for the above under the composite scheme is January 1, 2017. The Company is in the process of obtaining various statutory / judicial / other necessary approvals for the aforesaid scheme.
- The results for the quarter and period ended December 31, 2015 have been restated to comply with Ind AS to make them comparable with the current period. Also refer Note 2 above. Further, previous period figures have been regrouped / reclassified wherever necessary, to conform with the current period presentation.



By Order of the Board
 For and on behalf of Board of Directors

 Chairperson
 DIN No. 00135514

Place: Chennai
 Date: February 9, 2017

**FORTIS MALAR REPORTS Q3 FY17 REVENUE AT RS.36.27 CR, UP 9.5%
OPERATING PROFIT FOR THE QUARTER AT Rs 0.51 CR**

Chennai, February 9 2017: Fortis Malar Hospitals Limited, a subsidiary of Fortis Healthcare Limited, a leading integrated healthcare delivery provider in India, today announced its financial results for the quarter ended December 31, 2016.

Commenting on the results Mr Daljit Singh, Chairman, Fortis Malar Hospitals Limited, said, “The hospital has been rendering outstanding medical services in Chennai and has been warmly recognized by the public for its contribution to healthcare. It has been doing exceptional work and has achieved the unique distinction of completing over 140 heart transplants, reinforcing its position as a high quality super specialty tertiary care centre in Asia. Additionally, it has made a mark for itself by performing complex and high end surgeries particularly in cardiology, neurology, mother and child care, among others. I am delighted with the great work being done by our team of doctors, nurses, paramedics and other staff members and am confident that we will continue to deliver world class clinical programs, with consistently superior results in the future, as well.”

Financial Highlights for the Quarter (Q3 FY17)

- Fortis Malar Hospitals reported an operating revenue of Rs 36.27 Cr compared to Rs 33.12 Cr in the corresponding quarter of the previous year, a growth of 9.5%
- Operating profit for the quarter stood at Rs 0.51 Cr compared to Rs 1.49 Cr, in the corresponding quarter of the previous year.
- Net profit was at Rs 0.79 Cr compared to Rs.1.27 Cr, in the corresponding period of the last fiscal year.
- During the quarter, Fortis Malar witnessed growth in its key specialties, showing a markedly better performance in CTVS, Orthopaedics, and Gynecology which grew by

117%, 19%, and 11% respectively, compared to the corresponding quarter of the previous year.

Operational Highlights for the quarter

Successful Heart Transplants for Two young Iraqi Siblings at Fortis Malar Hospital

Mohammed Sabah Sulaiman and Safaa Sabah Sulaiman, aged 16 and 13 years respectively, were suffering from dilated cardiomyopathy, a condition in which the ventricles in the bottom chambers of the heart dilate and weaken. Reflecting its commitment to save lives by continuous improvement and innovation, the team of cardiac surgeons at Fortis Malar Hospital, in a rather rare operation, performed heart transplant surgeries on the duo successfully. The team led by Dr. K R Balakrishnan and Dr Suresh Rao , not only gave the duo a new lease of life, but also raised a ray of hope in many more children suffering from end stage heart failure.

Fortis Malar Hospital launches Happy Losers Club

During the quarter, Fortis Malar together with GEM Hospital, launched an initiative “Happy Losers Club” at Fortis Gem Centre for Obesity. This initiative was inaugurated by legendary singer S.P. Balasubrahmanyam. Happy Losers Club aims to provide support environment for those who have embarked on a path of weight loss and healthy living through bariatric surgery.

Corporate Social Responsibility

Playing its part as a good social corporate citizen, Fortis Malar has been involved in programmes that make a positive contribution to society. The following CSR activities were undertaken during the quarter:

- To support the national agenda set by the Hon'ble Prime Minister of India following demonetization, Fortis Malar Hospital extended its hands by offering free mineral water, juices, biscuits, medication and first aid kits to citizens waiting in line at ATMS and banks throughout the city of Chennai. More than 50 volunteers, including doctors & nurses, formed teams with 5-6 members each to drive this initiative.
- As a part of our All India Swachh Fortis initiative the staff at our hospital is voluntarily taking up the cleaning of areas surrounding the Malar hospital. The cleaning campaign by the staff is repeated on the last Wednesday of every month.

About Fortis Malar Hospitals Ltd

Fortis Malar Hospital (formerly known as Malar Hospital) was acquired by Fortis Healthcare (India) Limited in early 2008. The hospital founded in 1992, is established as one of the largest corporate hospitals in Chennai providing quality super specialty and multi-specialty healthcare services. Fortis Malar Hospitals, with 180 beds, focuses on providing comprehensive medical care in the areas of Cardiology and Cardiac Surgery, Neuro Surgery, Gynaecology, Orthopaedics, Gastroenterology, Neurology, Paediatrics, Diabetics, Nephrology and Internal Medicine.

Fortis Malar Hospital has a state of the art Cath Lab and multiple dedicated cardiac operation theatres and intensive coronary care units. Several rare and complex Adult and Paediatric Cardiac surgeries, Orthopedic and Joint replacements, Neurosurgeries and Plastic reconstruction surgeries have been performed at this hospital. The hospital's Obstetrics and Gynaecology services are among the busiest in the city, successfully performing many complicated deliveries and surgeries. They are supported by a dedicated Neonatology unit.

About Fortis Healthcare Ltd

Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Dubai, Mauritius and Sri Lanka with 45 healthcare facilities (including projects under development), approximately 10,000 potential beds and over 340 diagnostic centres

DISCLAIMER

This press release may contain forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this press release are cautioned not to place undue reliance on these forward-looking statements. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this press release, without obligation to notify any person of such revision or changes.

FOR MORE INFORMATION PLEASE CONTACT

Seetha.C

PR & Communications
Fortis Malar Hospitals Ltd
Mobile: 9176988775
seetha.c@fortishealthcare.com

Sumit Jain

K2 Communications Pvt Ltd
Mobile: 9886021715
Sumit.jain@k2communications.in